- Home
- All Companies
- Companies in B
- BG Medicine Inc.
- BG Medicine, Inc. (BGMD) - Product Pipeline Analysis
BG Medicine, Inc. (BGMD) - Product Pipeline Analysis
- Publication date: August 2012
- Report size: 37 pages
- Report price: $ 750
Get this report today!
Summary
Table of Contents
Data Series
BG Medicine, Inc. (BGMD) - Product Pipeline Analysis
Summary
BG Medicine, Inc. (BGM) is a biotechnology and pharmaceutical company, based in the US. The company discovers, develops and commercializes novel molecular diagnostics tests. It operates through product segments such as Galectin-3 and pipeline. BGM Galectin-3 test for heart failure is a novel diagnostic test for measuring galectin-3 levels in blood plasma or serum. Its pipeline product includes Galectin-3, Galectin-3 Post-MI, AMIPredict, LipidDx, multiple sclerosis and Anti-TNF alpha drug response. The company develops pipeline of molecular diagnostics that are utilized to aid in the diagnosis and treatment of various diseases, including cardiovascular diseases, cancer and central nervous system disorders. BGM is headquartered in Waltham
This report is a source for data, analysis and actionable intelligence on the BG Medicine, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.
Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.
Reasons to Buy
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.
Pathology Industry in the United States
- Publication date: August 2012
- Report size: 37 pages
- Report price: $ 750
Get this report today!
Talk to Alison
00 1 718 618 48 97
Search ReportLinker
The Largest Collection of Market Research Reports
» 450,000 Company Profiles
» 40,000 Country Guides
From +200,000 authoritative sources
Pathology Industry in the United States : Latest Reports
Therapy in United States: Type 2 Diabetes - Pipeline Review, H1 2012
- $ 2 500
- Company report
- March 2013
- by Global Markets Direct
This report provides data on the therapeutic development for Type 2 Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...
Rheumatoid Arthritis - Pipeline Review, H1 2013
- $ 2 500
- Company report
- March 2013
- by Global Markets Direct
Rheumatoid Arthritis - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Rheumatoid Arthritis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This ...
Pathology in United States: Breast Cancer - Pipeline Review, H1 2012
- $ 2 500
- Company report
- April 2013
- by Global Markets Direct
This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...
More Reports:
Pathology in China (78)
Pathology in France (143)
Pathology in Germany (145)
Pathology in Italy (144)
Pathology in Japan (152)
Pathology in Spain (144)
Pathology Industry in the United States : Latest Downloads
Company Report: Mental Health for Year 2013
- Company report
- April 2013
- 15 pages
... As locally as possible and reducing the need for hospital inpatient care wherever feasible. Acute, intermediate, community and mental health services are delivered across a network of community clinics ...
Company Report: Pathology for Year 2013
- Company report
- April 2013
- 25 pages
- by Research Paper
Company Report: Pathology for Year 2013
- Company report
- April 2013
- 35 pages
... Of glycemic control in adults and children with diabetes mellitus. Humalog S mechanism of action includes regulation of glucose metabolism, lowering of blood glucose by stimulating peripheral glucose uptake ...
Company Report: Pathology For Year 2013
2 months agoCompany Report: Pathology For Year 2013
2 months agoCompany Report: Pathology For Year 2013
3 months agoCompany Report: Pathology For Year 2013
3 months agoAccountable - Company Report For Year 2013
3 months agoCompany Report: Breast Cancer For Year 2013
3 months agoCompany Report: Pathology For Year 2013
3 months agoMore Reports:
Pathology in Australia (47)
Pathology in Canada (45)
Pathology in China (14)
Pathology in India (35)
Pathology in Ireland (19)
Related Market Segments :
Cardiovascular Disease
Neurological Disease
Multiple Sclerosis
Heart Failure
Acute Coronary Syndrome
Company Reports
Company Profiles
10 CompaniesHospital For Sick Children
CanadaAstraZeneca PLC
United KingdomSanofi-Aventis Senegal
SenegalSanofi Aventis S.A.
SpainNovartis Inc.
SwitzerlandBiogen Idec
United StatesBeth Israel Deaconess Medical Center Inc.
United StatesAcorda Therapeutics Inc.
United StatesGeneral Electric Co.
United Statesref:plp2012
Reportlinker.com © Copyright 2013. All rights reserved.
